Summary: Minocycline, a broad‑spectrum tetracycline antibiotic, has shown promise as an adjunctive treatment for major depressive disorder. Researchers suggest the drug may reduce inflammation in the brain—a factor implicated in some cases of depression—and a small randomized clinical trial found that people who received minocycline alongside their usual therapy reported better overall functioning, improved quality of life, and reduced anxiety symptoms compared with placebo.
Source: Deakin University.
Acne antibiotic minocycline shows potential to improve outcomes in major depression
A world‑first clinical trial led by Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) indicates that minocycline, an antibiotic commonly used for acne since the 1970s, may offer meaningful benefit when added to standard care for people with major depressive disorder.
The double‑blind, randomized, placebo‑controlled proof‑of‑concept trial enrolled 71 adults diagnosed with major depressive disorder. Participants continued their usual treatments and were randomized to receive either 200 mg/day of adjunctive minocycline or a matching placebo for 12 weeks. Researchers assessed depression and anxiety symptoms, global clinical impression, quality of life, and social and occupational functioning using validated rating scales.
Although the primary outcome—the change in Montgomery–Åsberg Depression Rating Scale (MADRS) score—did not differ significantly between the two groups at 12 weeks, the study found several other clinically relevant benefits favoring the minocycline group. At week 12, participants receiving minocycline showed significantly better Clinical Global Impression–Improvement scores, higher quality of life scores, and improved social and occupational functioning. These improvements persisted at the 16‑week follow‑up, and Patient Global Impression scores also became significantly better for the minocycline group.
Lead researcher Dr Olivia Dean explained the rationale behind testing an antibiotic as an antidepressant adjunct: emerging evidence links elevated inflammatory markers with major depressive disorder in a subset of patients. Minocycline has known anti‑inflammatory and neuroprotective properties in preclinical models—reducing microglial activation, oxidative stress, and promoting neuronal health—so researchers hypothesized it might address biological pathways not targeted by conventional antidepressants.
“Traditional antidepressants help many people, but a substantial proportion remain symptomatic or do not fully regain their prior level of functioning,” Dr Dean said. “Repurposing established medications with known safety profiles, like minocycline, could accelerate access to new, biologically informed treatment strategies for depression.”
The trial was relatively small and exploratory, so Dr Dean emphasized the need for larger, well‑powered studies to confirm these findings, refine optimal treatment duration, and identify which patients are most likely to benefit. The research team is seeking funding to expand the trial and is also exploring whether minocycline could help people with anxiety disorders, given the observed trends toward reduced anxiety symptoms.
Funding: This study was supported by Deakin University, the Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Barwon Health, Chulalongkorn University, the Brain & Behavior Foundation (USA), and an Australasian Society for Bipolar and Depressive Disorders/Servier grant.
Source: Deakin University
Image Source: NeuroscienceNews.com image used for illustrative purposes.
Original Research: “Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial” by Olivia M. Dean et al., published in Australian and New Zealand Journal of Psychiatry, published online June 3, 2017. DOI: 10.1177/0004867417709357
Abstract
Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial
Objective:
Current antidepressant treatments bring full remission in a minority of patients, underscoring the need for effective adjunctive options. Inflammation is increasingly recognized in the pathophysiology of major depressive disorder, and minocycline has properties that modulate immune‑inflammatory processes, reduce oxidative stress, and support neuronal survival. This trial evaluated 200 mg/day adjunctive minocycline, added to treatment as usual, in adults with major depressive disorder.
Methods:
Seventy‑one adults meeting DSM‑IV criteria for major depressive disorder were randomized in a 12‑week, double‑blind, placebo‑controlled trial. Outcomes included the Montgomery–Åsberg Depression Rating Scale (primary outcome), Clinical Global Impression–Improvement and Severity scales, Hamilton Anxiety Rating Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, Social and Occupational Functioning Scale, and the Range of Impaired Functioning Tool. The trial was registered on the Australian and New Zealand Clinical Trials Register (ACTRN12612000283875).
Results:
At week 12, mixed‑model repeated measures analysis showed no significant difference in MADRS scores between minocycline and placebo groups. However, minocycline produced significant benefits for Clinical Global Impression–Improvement (effect size −0.62, 95% CI [−1.8, −0.3], p = 0.02), Quality of Life Enjoyment and Satisfaction Questionnaire (effect size −0.12, 95% CI [0.0, 0.2], p < 0.001), and social and occupational functioning measures (effect size 0.79, 95% CI [−4.5, −1.4], p < 0.001). These improvements persisted at the 16‑week follow‑up, and Patient Global Impression also reached significance (effect size 0.57, 95% CI [−1.7, −0.4], p = 0.017).
Conclusion:
Although the study’s primary depression symptom measure did not show a significant group difference, consistent improvements across global clinical assessments, quality of life, and functioning suggest minocycline warrants further investigation as an accessible adjunctive therapy for major depressive disorder. Larger trials are needed to confirm these effects and clarify optimal use.